Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Mr. Daniel M. Niedzwiecki

Chief Administrative Officer, General Counsel & Corporate Secretary

Mr. Brian A. Markison

Chief Executive Officer & Director

Dr. Jean-Claude  Provost M.D.

Chief Medical Officer

Mr. Paul M. Blanchfield

President

Mr. Mark Richard Kinarney

Senior Director of Investor Relations

Mr. Robert J. Marshall Jr., CFA

Chief Financial Officer & Treasurer

Ms. Andrea  Sabens

Chief Accounting Officer

Ms. Dorothy  Barr

Senior Vice President of Manufacturing & Technical Operations

Ms. Carol  Walker

Senior Vice President of Quality

Ms. Linda S. Lennox

Vice President of Corporate Communications & Chief of Staff

Názov	Trhová kapitalizácia
China Medical System Holdings Limited	0M
TILT Holdings Inc.	0M
ZhuZhou QianJin Pharmaceutical Co.,Ltd	0M
Wockhardt Limited	0M
Chong Kun Dang Pharmaceutical Corp.	0.1M
Eris Lifesciences Limited	0M
Shenzhen Kangtai Biological Products Co., Ltd.	0M
Takeda Pharmaceutical Company Limited	0M
Medical Developments International Limited	0M
Alembic Pharmaceuticals Limited	0M
Hanmi Pharm. Co., Ltd.	0.3M

Lantheus Holdings, Inc.

Lantheus Holdings, Inc. Zoznam konkurentov

Hlavní konkurenti